SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term FOLD Investors to Contact the Firm


PHILADELPHIA, July 10, 2025 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Amicus Therapeutics, Inc. (NASDAQ: FOLD) ("Amicus") on behalf of the company's shareholders. 

(PRNewsfoto/Kaskela Law LLC)

Year to date, shares of Amicus' stock have declined over 32% in value, to trade at a current price of less than $7.00 per share. 

The investigation seeks to determine whether Amicus and/or the company's officers and directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions. 

Amicus shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional information about this investigation and their legal rights and options at (484) 229 – 0750, or by clicking on the following link (or by copying and pasting the link into your browser): 

https://kaskelalaw.com/case/amicus-therapeutics/ 

Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com. 

CONTACT: 

KASKELA LAW LLC
D. Seamus Kaskela, Esq. 
(skaskela@kaskelalaw.com) 
Adrienne Bell, Esq. 
(abell@kaskelalaw.com) 
18 Campus Blvd., Suite 100 
Newtown Square, PA 19073 
(484) 229 – 0750 
www.kaskelalaw.com 

This notice may constitute attorney advertising in certain jurisdictions. 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-notice-kaskela-law-llc-announces-shareholder-investigation-of-amicus-therapeutics-inc-nasdaq-fold-and-encourages-long-term-fold-investors-to-contact-the-firm-302501839.html

SOURCE Kaskela Law LLC

Aktuelle Amicus Therapeutics Aktie News

Werbung

Amicus Therapeutics Analysen

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Amicus Therapeutics nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
Datum Rating Analyst
17.06.19 Amicus Therapeutics Buy H.C. Wainwright & Co.
05.06.19 Amicus Therapeutics Overweight Cantor Fitzgerald
30.01.19 Amicus Therapeutics Overweight Cantor Fitzgerald
17.08.18 Amicus Therapeutics Neutral Chardan Capital Markets
13.09.17 Amicus Therapeutics Buy Chardan Capital Markets

Information


Die Handels- und Depotfunktionen in diesem Broker Cockpit werden für Finanzinstrumente von der Finanzen.net Zero GmbH als vertraglich gebundener Vermittler der DonauCapital Wertpapier GmbH (§ 3 Abs. 2 WpIG) bereitgestellt; bei Kryptowerten werden die Handels- und Depotfunktionen in diesem Broker Cockpit ausschließlich von der DonauCapital Wertpapier GmbH bereitgestellt. Die Finanzen.net GmbH stellt ausschließlich den technischen Rahmen bereit und ist in die Wertpapier- und Kryptodienstleistung nicht einbezogen.